



# NEXTGENERATION ANTIBODIES FOR CANCER DRUGS

COMBINING ANTIBODY THERAPIES FOR CANCER TREATMENTS  
TO INNOVATE BIOMEDICAL SCIENCE

SEPTEMBER 2<sup>ND</sup> 2009    HOTEL BEAU RIVAGE    GENEVA, SWITZERLAND

IN THE CHAIR:

**WILLY DE GREEF** SECRETARY GENERAL, EUROPABIO

HEAR FROM YOUR EMINENT SPEAKER PANEL:

**PROFESSOR JAN VAN DE WINKEL** CHIEF SCIENTIFIC OFFICER, GENMAB    **DR. WIM TIEST** DIRECTOR PROJECT OFFICE, IMMUNOTHERAPEUTICS BUSINESS UNIT, GLAXOSMITHKLINE BIOLOGICALS    **PROFESSOR PATRICK A. BAEUERLE** SENIOR VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER, MICROMET AG    **PROF. DR. MELVYN LITTLE** CHIEF SCIENTIFIC OFFICER, AFFIMED THERAPEUTICS AG    **DR. PABLO UMAÑA** CHIEF SCIENTIFIC OFFICER, GLYCART BIOTECHNOLOGY (ROCHE)    **DR. BJÖRN FRENDEUS** SENIOR PRINCIPAL SCIENTIST, PRECLINICAL RESEARCH, BIOINVENT INTERNATIONAL    **PROF. DR. CHRISTOPH RENNER** GROUP LEADER, DEPARTMENT OF ONCOLOGY, UNIVERSITY HOSPITAL ZURICH

**LAB** innovator

SEPTEMBER 1<sup>ST</sup> 2009

EVENING DINNER

20:00

## SEPTEMBER 2<sup>ND</sup> 2009, CONFERENCE

08:30

REGISTRATION AND COFFEE

09:00

**CHAIRMAN'S OPENING REMARKS**

Willy De Greef Secretary General  
EUROPABIO

09:10

**CREATING ANTIBODIES TO TARGET TUMOR CELLS AND TUMOR AREAS**

- Developing a programme for antibody and vaccine activities to be at the forefront of cancer treatments
- Exploiting the Phage-technology to generate and isolate antibodies for cancer treatments in the human body
- How do you best stimulate the immune system to target tumor cells
- Identifying technologies to optimise your drug discovery research
- Where do we go from here?

Prof. Dr. Christoph Renner Group Leader, Department of Oncology  
UNIVERSITY HOSPITAL ZURICH

09:55 CASE STUDY:

**BITE TECHNOLOGY: TEACHING ANTIBODIES AND T CELLS NEW TRICKS**

- Clinical proof of concept with BiTE antibody blinatumomab in the treatment of lymphoma and leukemia
- A BiTE antibody eliminating colorectal cancer stem cells
- Conversion of cetuximab and panitumumab into highly active BiTE antibodies
- Elimination of KRAS and BRAF expressing colon cancer cells by EGFR-specific BiTE antibodies
- A growing pipeline of BiTE antibodies for cancer treatment

Professor Patrick A. Baeuerle  
Senior Vice President and Chief Scientific Officer  
MICROMET AG

10:40

MORNING COFFEE

11:10 CASE STUDY:

**DEVELOPING INNOVATIVE ANTIBODY CANCER DRUGS TO BREAK NEW GROUNDS IN THE LIFE SCIENCE INDUSTRY**

- Mastering an R & D strategy to deliver better healthcare to the market in the 21st century
- Harnessing on anti-cancer agents to find new ways to activate the immune system
- Designing a combination antibody cancer therapy to reduce side effects in the human body
- How do you move your next generation antibody therapeutics forward?
- Examining best experiences so far

Dr. Björn Frendeus Senior Principal Scientist, Preclinical Research  
BIOINVENT INTERNATIONAL

11:55 KEYNOTE ADDRESS:

**TRANSLATIONAL RESEARCH: MASTERING A STRATEGY FOR CANCER TREATMENTS TO BREAK NEW SCIENTIFIC AND COMMERCIAL GROUNDS**

- Developing a holistic view on antibody-based cancer drugs & treatments in the 21<sup>st</sup> century
- How do you harness on the capabilities of antibody therapeutics for your oncology drug discovery research activities?
- Examining the development of "targeted" cancer therapy combinations to develop block busters to the global marketplace
- Uncovering best experiences learnt so far

Professor Jan van de Winkel Chief Scientific Officer  
GENMAB

12:40

LUNCHEON

#### 13:40 CASE STUDY:

##### COMBINED TREATMENTS: PIONEERING CANCER RESEARCH THROUGH NEW IDEAS & TECHNOLOGIES

- Collaborating with universities and pharmaceuticals to deliver combined antibody therapies for cancer treatments
- Enhancing new approaches to antibody engineering to strengthen your antibody cancer drug development
- Examining the role of emerging technology tools to transform

Biomedical science with regards to:

- Antibody engineering: Reducing side effects in the human body to maximise the commercial success of your cancer drugs
  - Genetic engineering technologies: Developing bispecific antibodies to target multiple cancer cells
  - Informatics: Integrating in vivo diagnostics and in vitro diagnostics to speed up your antibody cancer drug delivery to the market
- Understanding the role of antibodies to identify new therapeutic cancer targets

Prof. Dr. Melvyn Little Chief Scientific Officer  
AFFIMED THERAPEUTICS AG

#### 14:25 CASE STUDY:

##### ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPY: FROM PERSPECTIVES TO REALITY

- Mastering an activate immunotherapy vision to enable your R & D organisation to deliver innovative cancer drugs and treatments to the market
- Personalising immunotherapies to diversify your pipeline of vaccine-related cancer drugs
- Examining the benefits with activate immunotherapies with regards to:
  - Lead identification and optimisation: Activating immune cells to identify best cancer drug candidates
  - Drug discovery research: Exploiting a versatile treatment strategy to develop cancer vaccines to the market
- The next generation cancer drugs: How do you move from antibody to vaccine delivery?

Dr. Wim Tiest Director Project Office, Immunotherapeutics Business Unit  
GLAXOSMITHKLINE BIOLOGICALS

15:10

AFTERNOON TEA

#### 15:40 CASE STUDY:

##### MASTERING AN R & D VISION FOR ANTIBODY CANCER DRUGS TO POSITION YOUR COMPANY IN THE FOREFRONT OF SCIENTIFIC DISCOVERIES

- Developing a combined cancer treatment strategy to provide better healthcare in the 21st century
- Establishing partnerships with the academic community to innovate your drug discovery research
- Integrating antibodies with conventional cancer drugs to personalise your drug treatments
- How do you capture the potential of monoclonal antibody in your cancer research?
- Monoclonal antibodies: Stimulating the immune system to deliver efficient cancer drug treatments

Dr. Pablo Umaña Chief Scientific Officer  
GLYCART BIOTECHNOLOGY (ROCHE)

#### 16:25 SPEAKER PANEL:

##### CAPTURING THE POTENTIAL OF ANTIBODIES FOR CANCER DRUGS TO STAY AHEAD OF YOUR COMPETITORS

Speakers from the day will share their best insights on how to commercialise your scientific discoveries within antibody cancer drugs in collaborative partnership between the industrial and academic communities around the World.

17:10

##### CHAIRMAN'S CLOSING REMARKS

17:20

##### END OF CONFERENCE

Lab Innovator invites you to remain for a cocktail reception immediately following the conference.

#### OFFICIAL PUBLICATION

Science magazine is published by the American Association for the Advancement of Science (AAAS), the world's largest general scientific society. [www.sciencemag.org](http://www.sciencemag.org)



# NEXT GENERATION ANTIBODIES FOR CANCER DRUGS

CONFERENCE CODE: LI024

PLEASE COMPLETE THIS FORM AND FAX BACK TO: +45 3313 6253

# LAB innovator

## REGISTRATION CONTRACT:

Name
Position
Name
Position
Name
Position

Please send any further names and positions on a separate page.

Organisation				
Address				
City				
Postcode				
Country				
Phone				
Fax				
Email				
Organisation No.				
Nature of Business				
Organisation size, circle one	-100	100+	250+	500+

## CONFERENCE FEES

Host your top clients or your own team for professional development. A superb opportunity for groups of three or more delegates at preferential rates:

1-2 Attendees, including Documentation package	per delegate:	1.343 EUR / 9.995 DKK
3+ Attendees, including Documentation package	per delegate:	1.007 EUR / 7.495 DKK
Additional Documentation package, Qty:	per package:	335 EUR / 2.495 DKK
V.I.P. client code:		

## EVENING DINNER:

Number of Attendees to the September 1 <sup>st</sup> Evening Dinner:	per delegate:	134 EUR / 999 DKK
Number requiring Vegetarian for Evening Dinner and/or Luncheon:		

## ACCOMMODATION:

Request Accommodation Booking at Hotel Beau Rivage to a reduced rate of 514,25 CHF.

Room(s) for	night(s)
-------------	----------

An 18 % service charge has been added to all conference fees prior to the event and is inclusive of programme materials, luncheon and refreshments. All prices excluding 25 % VAT. Payment is required within 30 working days.

Print Name:
Signatur:
Date:

## SPONSORSHIP AND EXHIBITION OPPORTUNITIES

Lab Innovator offers a limited number of sponsorship, exhibition, advertising and marketing packages to provide your company with the possibility to position yourself as a market leader to your target audience.

For details about the wide range of opportunities available, from insertion of promotional materials in the delegate package to full conference sponsorship package, please contact:

Kenneth Skjøtt Stagis Toft on +45 3313 6250 or by email: [kst@labinnovator.com](mailto:kst@labinnovator.com)

## 4 EASY WAYS TO REGISTER:

**Fax**  
+ 45 3313 6253

**Phone**  
+ 45 3313 6250

**E-mail**  
[registration@labinnovator.com](mailto:registration@labinnovator.com)

**Mail**  
Lab Innovator  
P. O. Box 374  
DK-1504 Copenhagen V

### Cancellations

By completing this registration form, the client hereby agrees that Lab Innovator will not be able to mitigate its losses for any less than 50 % of the total contract value. Cancellations must be received by mail or fax three weeks before the conference. Thereafter the full conference price is payable. Delegate substitutions are welcome at any time. If for any reason Lab Innovator decides to amend this conference, we are not responsible for covering airfare, hotel or other costs incurred by registrants. In the event that Lab Innovator cancels the event, Lab Innovator reserves the right to transfer this booking to another conference to be held in the twelve months, or to provide a credit of an equivalent amount to another conference within the same sector within the following twelve months.  
Indemnity: Should, for any reasons outside the control of Lab Innovator, the venue or speakers change or the event be cancelled due to an act of terrorism, extreme weather conditions or industrial action, Lab Innovator shall endeavour to re-schedule, the client hereby indemnifies and holds Lab Innovator harmless from and against any and all costs, damages and expenses, including legal fees, which are incurred by the client. The construction, validity and performance of this agreement shall be governed in all respects by the laws of Denmark to the exclusive jurisdiction of whose courts the Parties hereby agree to submit.